Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome
“Despite incredible advancements for patients with other hematological malignancies, the treatment landscape in MDS has remained unchanged for many years, with no new
LLS will fund Forty Seven’s efforts in MDS through its Therapy Acceleration Program® (TAP), a strategic initiative to partner directly with innovative biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers. Under the collaboration, Forty Seven will use LLS TAP funding and leverage LLS value-added resources for 5F9 in MDS. Pursuant to this new LLS TAP funding, Forty Seven is eligible for up to
“LLS has a deep commitment to hematological diseases, as well as an extensive network in the field. We are honored by their continued support, which reinforces 5F9’s potential as a novel therapy for MDS. This funding comes at an opportune time, as we plan to initiate our first registration-enabling trial early next year, with the hope of achieving an approval to benefit patients,” said
“MDS is estimated to impact between 60,000 and 170,000 patients in
5F9 is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the "don't eat me" signal used by cancer cells to avoid being ingested by macrophages.
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in
For additional information visit lls.org/lls-newsnetwork. Follow LLS on
About Therapy Acceleration Program® (TAP)
The Leukemia & Lymphoma Society’s Therapy Acceleration Program (TAP) funds innovative projects related to therapies that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need. TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain the resources they need or a partner to complete the testing, registration and marketing of new treatments for leukemia, lymphoma and myeloma. TAP funding is different from the traditional LLS research grant. The TAP review process is separate from the grant process and LLS’s TAP staff play an active advisory role and closely monitor each approved project. To learn more about how TAP works, please click here.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," “potential,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Forty Seven’s plan to initiate a single-arm potentially, registration-enabling trial in higher-risk MDS patients in the first quarter of 2020 and that this trial could support a Biologics Licensing Application filing with the
For more information please visit www.fortyseveninc.com or contact email@example.com.
For journalist enquiries please contact
For investor enquiries please contact
Source: Forty Seven, Inc.